Partnership & Sponsors
Global Blood Therapeutics
South San Francisco, California
GBT seeks to improve the lives of those with sickle cell disease by combining focused science with compassion and collaboration. Our deep commitment to partnering and advocating for the sickle cell community is our guiding light. We prioritize listening to and understanding the perspectives, interests and challenges patients face so we can develop important new investigational treatments and support access to care. We work with various stakeholders to transform the quality of the care provided to people with SCD.
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities.
GBT is developing its late-stage product
candidate, Voxelotor (previously
called GBT440), for the treatment
of sickle cell disease.
GBT Announces Presentation of Six
Studies at ASH Supporting Voxelotor
Sickle Cell Disease (SCD) Program.
For more info www.gbt.com
Spread awareness of sickle cell anemia
Provide support to the families coping with a diagnosis of this disease.
“To increase the quality of life for individuals diagnosed with sickle cell disease in California by ensuring expert, unbiased, and comprehensive care.”
A medical system that effectively addresses the unique needs of individuals with sickle cell disease
Patients who are empowered and equipped to advocate for themselves.
Networking California for Sickle Cell Care
"The Networking California for Sickle Cell Care Initiative (NCSCC) was developed through advocacy and stakeholder engagement supported by data."
For More Information:
Foundation for Sickle Cell Disease Research
Foundation for Sickle Cell Disease Research (FSCDR) was founded by Dr. Lanetta Bronté in December 2012 after working closely with the sickle cell community and noticing the extreme lack of care for a disease that affects 3 million people nationwide. Dr. Bronté serves as principal investigator on grants and industry-sponsored trials in sickle cell disease.
The FSCDR is a comprehensive, non-profit organization that provides a platform for researchers, healthcare providers, and those living with sickle cell disease. Working collaboratively with academia, pharmaceutical, biotechnology, and community organizations, the best practices are identified to help with the management and future care of people living with sickle cell disease. We are accepting new clients daily and also offer free screenings. Know your sickle cell status!
To learn more, visit FSCDR at http://fscdr.org
UCSF Benioff Children's Hospital
West SCD CTN Data Registry
In collaboration with the American society of hematology, SCAASF is a part of the community advisory board for Clinical Trials Network.
American Society of Hematology
American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.